Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14435MR)

This product GTTS-WQ14435MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14435MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4145MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ9560MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ7163MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ5884MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ12462MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ13781MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ1647MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ1893MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGEN2034
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW